<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01831427</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-326-0101</org_study_id>
    <secondary_id>2013-000305-23</secondary_id>
    <nct_id>NCT01831427</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 (Andecaliximab) in Adults With Moderate to Severe Active Ulcerative Colitis</brief_title>
  <official_title>A Phase 1 Double-blind, Randomized, Placebo-Controlled, Staggered, Single and Multiple Ascending Dose, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 in Subjects With Moderate to Severe Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are as follows:&#xD;
&#xD;
        -  To assess the safety and tolerability of escalating single and multiple doses of GS-5745&#xD;
           (andecaliximab) in participants with moderate to severe ulcerative colitis (UC) as&#xD;
           assessed by adverse events (AEs) and laboratory abnormalities&#xD;
&#xD;
        -  To assess the pharmacokinetics (PK) of GS-5745 (andecaliximab) in participants with&#xD;
           moderate to severe UC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will test the safety of the drug. Participants will be given different&#xD;
      concentrations of the drug in Cohorts, starting from a lower dose to a higher dose.&#xD;
&#xD;
      Single-Dose Treatment:&#xD;
&#xD;
      A thorough assessment of safety and tolerability will be performed before escalating to the&#xD;
      next higher dose. For example, the first 2 participants will be dosed in a staggered fashion&#xD;
      24 hours apart. Provided that there are no significant safety signals up to 24 hours&#xD;
      post-dose for the first 2 participants, the remaining 4 participants will be dosed. A&#xD;
      thorough assessment of safety and tolerability (through Day 14 post-dose) will be performed&#xD;
      by the safety review committee before escalating to the next higher dose. Participants&#xD;
      enrolled in a SAD cohort will be eligible to participate in a MAD or adaptive MAD cohort if&#xD;
      eligibility criteria are met.&#xD;
&#xD;
      Multiple-Dose Treatment:&#xD;
&#xD;
      This design follows the same set-up as the Single-Dose Treatment. Dosing will not commence in&#xD;
      the first MAD cohort until safety data from the second dose level SAD cohort has been&#xD;
      reviewed through Day 15. Successive MAD cohorts will only be dosed after safety data from the&#xD;
      previous, lower dose MAD cohort through Day 43 and the next higher dose SAD cohort through&#xD;
      Day 15, have been reviewed by the safety review committee. An additional Adaptive MAD cohort&#xD;
      will explore a subcutaneous dosing of andecaliximab 150 mg prefilled syringe once a week for&#xD;
      5 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 28, 2013</start_date>
  <completion_date type="Actual">February 6, 2015</completion_date>
  <primary_completion_date type="Actual">January 5, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced Any Treatment-Emergent Adverse Events (TEAEs) (SAD/MAD)</measure>
    <time_frame>SAD Cohorts: First dose date (Day 1) plus 30 days, MAD/Adaptive MAD Cohort: First dose date up to last dose date (Maximum: Day 29) plus 30 days</time_frame>
    <description>TEAEs are any AEs with an onset date of on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug or any AEs leading to premature discontinuation of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: Cmax (SAD)</measure>
    <time_frame>Predose and 1, 2, and 6 hours postdose on Day 1; Days 2, 3, 8, 15, 29, and 43</time_frame>
    <description>Cmax is defined as the maximum concentration of drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: Cmax (MAD)</measure>
    <time_frame>MAD Cohorts: Predose and 1, 2, and 6 hours postdose on Days 1 and 29, Predose on Days 8 and 36; Adaptive MAD Cohort: Predose and 6 hours postdose on Days 1, and 29, Predose on Days 8 and 36</time_frame>
    <description>Cmax is defined as the maximum concentration of drug over the dosing interval. Data for Day 1 was based on the data collected from Day 1 through Day 8. Data for Day 29 was based on the data collected from Day 29 through Day 36.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: Ctau (MAD)</measure>
    <time_frame>MAD Cohorts: Predose and 1, 2, and 6 hours postdose on Day 29; Predose on Day 36; Adaptive MAD Cohort: Predose and 6 hours postdose on Day 29; Predose on Day 36</time_frame>
    <description>Ctau is defined as the observed drug concentration at the end of the dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: AUCinf (SAD)</measure>
    <time_frame>Predose and 1, 2, and 6 hours postdose on Day 1; Days 2, 3, 8, 15, 29, and 43</time_frame>
    <description>AUCinf is defined as the area under the plasma concentration versus time curve extrapolated to infinite time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: AUCtau (MAD)</measure>
    <time_frame>MAD Cohorts: Predose and 1, 2, and 6 hours postdose on Days 1 and 29; Predose on Days 8 and 36; Adaptive MAD Cohort: Predose and 6 hours postdose on Days 1, and 29; Predose on Days 8 and 36</time_frame>
    <description>AUCtau is defined as the area under the plasma concentration versus time curve over the dosing interval. Data for Day 1 was based on the data collected from Day 1 through Day 8. Data for Day 29 was based on the data collected from Day 29 through Day 36.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: AUClast (SAD)</measure>
    <time_frame>Predose and 1, 2, and 6 hours postdose on Day 1; Days 2, 3, 8, 15, 29, and 43</time_frame>
    <description>AUClast is defined as the area under the plasma concentration versus time curve from time zero to the last observable concentration.</description>
  </primary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Andecaliximab 0.3 mg/kg IV single ascending dose (SAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive andecaliximab 0.3 milligrams per kilogram (mg/kg) on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Andecaliximab 1.0 mg/kg IV (SAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive andecaliximab 1.0 mg/kg on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Andecaliximab 2.5 mg/kg IV (SAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive andecaliximab 2.5 mg/kg on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Andecaliximab 5.0 mg/kg IV (SAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive andecaliximab 5.0 mg/kg on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Pooled (SAD)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Andecaliximab 0.3 mg/kg IV multiple ascending doses (MAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive andecaliximab 0.3 mg/kg on Days 1, 15, and 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Andecaliximab 1.0 mg/kg IV (MAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive andecaliximab 1.0 mg/kg on Days 1, 15, and 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Andecaliximab 2.5 mg/kg IV (MAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive andecaliximab 2.5 mg/kg on Days 1, 15, and 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Andecaliximab 5.0 mg/kg IV (MAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive andecaliximab 5.0 mg/kg on Days 1, 15, and 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Andecaliximab 150 mg SC (Adaptive MAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive andecaliximab 150 mg on Days 1, 8, 15, 22, and 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Pooled (MAD)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo on Days 1, 15, and 29.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Andecaliximab</intervention_name>
    <description>Andecaliximab administered by intravenous (IV) infusion or subcutaneous (SC) injection</description>
    <arm_group_label>Andecaliximab 0.3 mg/kg IV multiple ascending doses (MAD)</arm_group_label>
    <arm_group_label>Andecaliximab 0.3 mg/kg IV single ascending dose (SAD)</arm_group_label>
    <arm_group_label>Andecaliximab 1.0 mg/kg IV (MAD)</arm_group_label>
    <arm_group_label>Andecaliximab 1.0 mg/kg IV (SAD)</arm_group_label>
    <arm_group_label>Andecaliximab 150 mg SC (Adaptive MAD)</arm_group_label>
    <arm_group_label>Andecaliximab 2.5 mg/kg IV (MAD)</arm_group_label>
    <arm_group_label>Andecaliximab 2.5 mg/kg IV (SAD)</arm_group_label>
    <arm_group_label>Andecaliximab 5.0 mg/kg IV (MAD)</arm_group_label>
    <arm_group_label>Andecaliximab 5.0 mg/kg IV (SAD)</arm_group_label>
    <other_name>GS-5745</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match Andecaliximab</intervention_name>
    <description>Placebo to match andecaliximab administered by IV infusion</description>
    <arm_group_label>Placebo Pooled (MAD)</arm_group_label>
    <arm_group_label>Placebo Pooled (SAD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Male or Female, 18 to 65 years of age&#xD;
&#xD;
          -  Negative pregnancy test at screening&#xD;
&#xD;
          -  Documented diagnosis of UC with a minimum disease extent of 15 centimeters (cm) from&#xD;
             the anal verge&#xD;
&#xD;
          -  Mayo Score of at least 3 for the SAD cohort and Mayo Score of at least 6 for the MAD&#xD;
             cohorts&#xD;
&#xD;
          -  Hepatic panel (aspartate aminotransferase [AST], alanine aminotransferase [ALT], total&#xD;
             bilirubin, direct bilirubin, alkaline phosphatase, lactate dehydrogenase [LDH] ≤ 2&#xD;
             times the upper limit of the normal range [ULN])&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 times the ULN&#xD;
&#xD;
          -  Hemoglobin ≥ 10 grams per deciliter (g/dL) (both males and females)&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (1,500 milli meters [mm]^3)&#xD;
&#xD;
          -  Platelets ≥ 100 x 10^9/L.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Exhibit severe UC/ clinically significant active infection&#xD;
&#xD;
          -  Current use of oral corticosteroids at a dose equivalent to &gt; 20 mg/day of prednisone&#xD;
&#xD;
          -  Any dose adjustment in oral corticosteroids or oral immunosuppressants (6-MP,&#xD;
             Azathioprine), or oral 5-aminosalicylate (5-ASA) compounds within 30 days of Baseline&#xD;
&#xD;
          -  Use of rectal formulations of 5-ASA compounds or corticosteroids within 2 weeks prior&#xD;
             to randomization&#xD;
&#xD;
          -  Crohn's disease or indeterminate colitis&#xD;
&#xD;
          -  History of colectomy, partial colectomy, or dysplasia on biopsy&#xD;
&#xD;
          -  Stool sample positive for Clostridium difficile (C. difficile) toxin, E. coli,&#xD;
             Salmonella, Shigella, Campylobacter or Yersinia&#xD;
&#xD;
          -  Treatment with Infliximab, Adalimumab, Natalizumab, Golimumab, Vedolizumab or&#xD;
             Certolizumab within 8 weeks of randomization&#xD;
&#xD;
          -  Any chronic medical condition (including, but not limited to, cardiac or pulmonary&#xD;
             disease) that, in the opinion of the Investigator, would make the individual&#xD;
             unsuitable for the study or would prevent compliance with the study protocol.&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Delta Research Partners LLC</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889-5600</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Michigan</name>
      <address>
        <city>Chesterfield Township, MI 48047</city>
        <state>Michigan</state>
        <zip>48047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ehrhardt Clinical Research, LLC</name>
      <address>
        <city>Belton</city>
        <state>Missouri</state>
        <zip>64012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GIRI</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LHSC University Campus</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharma Center of Kenezy Gyula Korhaz Rendelointezet</name>
      <address>
        <city>Debrecen</city>
        <state>Hajdú-Bihar</state>
        <zip>4031</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem Altalanos Orvostudomanyi Kar</name>
      <address>
        <city>Budapest</city>
        <state>Pest</state>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drug Research Centre</name>
      <address>
        <city>Balatonfured</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Hospital</name>
      <address>
        <city>Chisinau</city>
        <zip>2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Pulmonology &quot;Marius Nasta&quot;</name>
      <address>
        <city>Bucharest</city>
        <zip>050159</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Hungary</country>
    <country>Moldova, Republic of</country>
    <country>Netherlands</country>
    <country>Romania</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bhandari BR, Fogel R, Onken J, Yen EH, Kanwar B, Subramanian GM, McHutchison GJ, et al. Safety and Efficacy of GS-5745 an Anti-Matrix Metalloproteinase 9 (MMP) Monoclonal Antibody in Patients with Moderately to Severely Active Ulcerative Colitis. Gastroenterology 2015;148 (4): S-1196.</citation>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 8, 2013</study_first_submitted>
  <study_first_submitted_qc>April 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2013</study_first_posted>
  <results_first_submitted>November 17, 2020</results_first_submitted>
  <results_first_submitted_qc>January 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 1, 2021</results_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at study sites in the United States, and Europe. The first participant was screened on 28 March 2013. The last study visit occurred on 06 February 2015.</recruitment_details>
      <pre_assignment_details>124 participants were screened.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Andecaliximab 0.3 mg/kg IV Single Ascending Dose (SAD)</title>
          <description>Participants received a single intravenous (IV) infusion of andecaliximab 0.3 milligrams per kilogram (mg/kg) on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Andecaliximab 1.0 mg/kg IV (SAD)</title>
          <description>Participants received a single IV infusion of andecaliximab 1.0 mg/kg on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>Andecaliximab 2.5 mg/kg IV (SAD)</title>
          <description>Participants received a single IV infusion of andecaliximab 2.5 mg/kg on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>Andecaliximab 5.0 mg/kg IV (SAD)</title>
          <description>Participants received a single IV infusion of andecaliximab 5.0 mg/kg on Day 1.</description>
        </group>
        <group group_id="P5">
          <title>Placebo Pooled (SAD)</title>
          <description>Participants received a single IV infusion of placebo on Day 1.</description>
        </group>
        <group group_id="P6">
          <title>Andecaliximab 0.3 mg/kg IV Multiple Ascending Doses (MAD)</title>
          <description>Participants received 3 single IV infusions of andecaliximab 0.3 mg/kg on Days 1, 15, and 29.</description>
        </group>
        <group group_id="P7">
          <title>Andecaliximab 1.0 mg/kg IV (MAD)</title>
          <description>Participants received 3 single IV infusions of andecaliximab 1.0 mg/kg on Days 1, 15, and 29.</description>
        </group>
        <group group_id="P8">
          <title>Andecaliximab 2.5 mg/kg IV (MAD)</title>
          <description>Participants received 3 single IV infusions of andecaliximab 2.5 mg/kg on Days 1, 15, and 29.</description>
        </group>
        <group group_id="P9">
          <title>Andecaliximab 5.0 mg/kg IV (MAD)</title>
          <description>Participants received 3 single IV infusions of andecaliximab 5.0 mg/kg on Days 1, 15, and 29.</description>
        </group>
        <group group_id="P10">
          <title>Andecaliximab 150 mg SC (Adaptive MAD)</title>
          <description>Participants received 5 single subcutaneous (SC) doses of andecaliximab 150 mg on Days 1, 8, 15, 22, and 29.</description>
        </group>
        <group group_id="P11">
          <title>Placebo Pooled (MAD)</title>
          <description>Participants received 3 single IV infusions of placebo on Days 1, 15, and 29.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="10"/>
                <participants group_id="P11" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="7"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="9"/>
                <participants group_id="P11" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator's Discretion</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Safety Analysis Set included participants who received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Andecaliximab 0.3 mg/kg IV (SAD)</title>
          <description>Participants received a single IV infusion of andecaliximab 0.3 mg/kg on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Andecaliximab 1.0 mg/kg IV (SAD)</title>
          <description>Participants received a single IV infusion of andecaliximab 1.0 mg/kg on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Andecaliximab 2.5 mg/kg IV (SAD)</title>
          <description>Participants received a single IV infusion of andecaliximab 2.5 mg/kg on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>Andecaliximab 5.0 mg/kg IV (SAD)</title>
          <description>Participants received a single IV infusion of andecaliximab 5.0 mg/kg on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>Placebo Pooled (SAD)</title>
          <description>Participants received a single IV infusion of placebo on Day 1.</description>
        </group>
        <group group_id="B6">
          <title>Andecaliximab 0.3 mg/kg IV (MAD)</title>
          <description>Participants received 3 single IV infusions of andecaliximab 0.3 mg/kg on Days 1, 15, and 29.</description>
        </group>
        <group group_id="B7">
          <title>Andecaliximab 1.0 mg/kg IV (MAD)</title>
          <description>Participants received 3 single IV infusions of andecaliximab 1.0 mg/kg on Days 1, 15, and 29.</description>
        </group>
        <group group_id="B8">
          <title>Andecaliximab 2.5 mg/kg IV (MAD)</title>
          <description>Participants received 3 single IV infusions of andecaliximab 2.5 mg/kg on Days 1, 15, and 29.</description>
        </group>
        <group group_id="B9">
          <title>Andecaliximab 5.0 mg/kg IV (MAD)</title>
          <description>Participants received 3 single IV infusions of andecaliximab 5.0 mg/kg on Days 1, 15, and 29.</description>
        </group>
        <group group_id="B10">
          <title>Andecaliximab 150 mg SC (Adaptive MAD)</title>
          <description>Participants received 5 single SC doses of andecaliximab 150 mg on Days 1, 8, 15, 22, and 29.</description>
        </group>
        <group group_id="B11">
          <title>Placebo Pooled (MAD)</title>
          <description>Participants received 3 single IV infusions of placebo on Days 1, 15, and 29.</description>
        </group>
        <group group_id="B12">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="4"/>
            <count group_id="B6" value="8"/>
            <count group_id="B7" value="8"/>
            <count group_id="B8" value="8"/>
            <count group_id="B9" value="8"/>
            <count group_id="B10" value="10"/>
            <count group_id="B11" value="8"/>
            <count group_id="B12" value="74"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" spread="11.3"/>
                    <measurement group_id="B2" value="37" spread="11.3"/>
                    <measurement group_id="B3" value="45" spread="15.4"/>
                    <measurement group_id="B4" value="42" spread="12.9"/>
                    <measurement group_id="B5" value="41" spread="15.1"/>
                    <measurement group_id="B6" value="42" spread="13.9"/>
                    <measurement group_id="B7" value="39" spread="11.7"/>
                    <measurement group_id="B8" value="38" spread="13.7"/>
                    <measurement group_id="B9" value="50" spread="9.8"/>
                    <measurement group_id="B10" value="48" spread="8.8"/>
                    <measurement group_id="B11" value="44" spread="15.8"/>
                    <measurement group_id="B12" value="43" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="10"/>
                    <measurement group_id="B11" value="8"/>
                    <measurement group_id="B12" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Not permitted means not permitted to ask due to local regulations.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="8"/>
                    <measurement group_id="B12" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Permitted</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experienced Any Treatment-Emergent Adverse Events (TEAEs) (SAD/MAD)</title>
        <description>TEAEs are any AEs with an onset date of on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug or any AEs leading to premature discontinuation of study drug.</description>
        <time_frame>SAD Cohorts: First dose date (Day 1) plus 30 days, MAD/Adaptive MAD Cohort: First dose date up to last dose date (Maximum: Day 29) plus 30 days</time_frame>
        <population>The Safety Analysis Set included participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Andecaliximab 0.3 mg/kg IV (SAD)</title>
            <description>Participants received a single IV infusion of andecaliximab 0.3 mg/kg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Andecaliximab 1.0 mg/kg IV (SAD)</title>
            <description>Participants received a single IV infusion of andecaliximab 1.0 mg/kg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Andecaliximab 2.5 mg/kg IV (SAD)</title>
            <description>Participants received a single IV infusion of andecaliximab 2.5 mg/kg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Andecaliximab 5.0 mg/kg IV (SAD)</title>
            <description>Participants received a single IV infusion of andecaliximab 5.0 mg/kg on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Andecaliximab IV Combined (SAD)</title>
            <description>Participants who received a single IV infusion of andecaliximab (0.3, 1.0, 2.5 and 5.0 mg/kg on Day 1) were combined in this arm.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Pooled (SAD)</title>
            <description>Participants received a single IV infusion of placebo on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Andecaliximab 0.3 mg/kg IV (MAD)</title>
            <description>Participants received 3 single IV infusions of andecaliximab 0.3 mg/kg on Days 1, 15, and 29.</description>
          </group>
          <group group_id="O8">
            <title>Andecaliximab 1.0 mg/kg IV (MAD)</title>
            <description>Participants received 3 single IV infusions of andecaliximab 1.0 mg/kg on Days 1, 15, and 29.</description>
          </group>
          <group group_id="O9">
            <title>Andecaliximab 2.5 mg/kg IV (MAD)</title>
            <description>Participants received 3 single IV infusions of andecaliximab 2.5 mg/kg on Days 1, 15, and 29.</description>
          </group>
          <group group_id="O10">
            <title>Andecaliximab 5.0 mg/kg IV (MAD)</title>
            <description>Participants received 3 single IV infusions of andecaliximab 5.0 mg/kg on Days 1, 15, and 29.</description>
          </group>
          <group group_id="O11">
            <title>Andecaliximab IV Combined (MAD)</title>
            <description>Participants who received 3 single IV infusions of andecaliximab (0.3, 1.0, 2.5, 5.0 mg/kg on Days 1, 15, and 29) were combined in this arm.</description>
          </group>
          <group group_id="O12">
            <title>Andecaliximab 150 mg SC (Adaptive MAD)</title>
            <description>Participants received 5 single SC doses of andecaliximab 150 mg on Days 1, 8, 15, 22, and 29.</description>
          </group>
          <group group_id="O13">
            <title>Andecaliximab IV+SC Combined (MAD)</title>
            <description>Participants who received 3 single IV infusions of andecaliximab (0.3, 1.0, 2.5, 5.0 mg/kg on Days 1, 15, and 29) and 5 single SC dose of andecaliximab (150 mg on Days 1, 8, 15, 22, and 29) were combined in this arm.</description>
          </group>
          <group group_id="O14">
            <title>Placebo Pooled (MAD)</title>
            <description>Participants received 3 single IV infusions of placebo on Days 1, 15, and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Any Treatment-Emergent Adverse Events (TEAEs) (SAD/MAD)</title>
          <description>TEAEs are any AEs with an onset date of on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug or any AEs leading to premature discontinuation of study drug.</description>
          <population>The Safety Analysis Set included participants who received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="32"/>
                <count group_id="O12" value="10"/>
                <count group_id="O13" value="42"/>
                <count group_id="O14" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="20.0"/>
                    <measurement group_id="O3" value="20.0"/>
                    <measurement group_id="O4" value="60.0"/>
                    <measurement group_id="O5" value="25.0"/>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="25.0"/>
                    <measurement group_id="O8" value="75.0"/>
                    <measurement group_id="O9" value="62.5"/>
                    <measurement group_id="O10" value="62.5"/>
                    <measurement group_id="O11" value="56.3"/>
                    <measurement group_id="O12" value="50.0"/>
                    <measurement group_id="O13" value="54.8"/>
                    <measurement group_id="O14" value="62.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic (PK) Parameter: Cmax (SAD)</title>
        <description>Cmax is defined as the maximum concentration of drug.</description>
        <time_frame>Predose and 1, 2, and 6 hours postdose on Day 1; Days 2, 3, 8, 15, 29, and 43</time_frame>
        <population>Participants in the PK Analysis Set (who received at least 1 dose of study drug and had at least 1 non-missing post dose concentration value for the corresponding analyte in plasma) for the SAD cohorts were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Andecaliximab 0.3 mg/kg IV (SAD)</title>
            <description>Participants received a single IV infusion of andecaliximab 0.3 mg/kg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Andecaliximab 1.0 mg/kg IV (SAD)</title>
            <description>Participants received a single IV infusion of andecaliximab 1.0 mg/kg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Andecaliximab 2.5 mg/kg IV (SAD)</title>
            <description>Participants received a single IV infusion of andecaliximab 2.5 mg/kg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Andecaliximab 5.0 mg/kg IV (SAD)</title>
            <description>Participants received a single IV infusion of andecaliximab 5.0 mg/kg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) Parameter: Cmax (SAD)</title>
          <description>Cmax is defined as the maximum concentration of drug.</description>
          <population>Participants in the PK Analysis Set (who received at least 1 dose of study drug and had at least 1 non-missing post dose concentration value for the corresponding analyte in plasma) for the SAD cohorts were analyzed.</population>
          <units>micrograms per milliliter (μg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="3.28"/>
                    <measurement group_id="O2" value="32.7" spread="11.08"/>
                    <measurement group_id="O3" value="77.8" spread="20.67"/>
                    <measurement group_id="O4" value="210.0" spread="102.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameter: Cmax (MAD)</title>
        <description>Cmax is defined as the maximum concentration of drug over the dosing interval. Data for Day 1 was based on the data collected from Day 1 through Day 8. Data for Day 29 was based on the data collected from Day 29 through Day 36.</description>
        <time_frame>MAD Cohorts: Predose and 1, 2, and 6 hours postdose on Days 1 and 29, Predose on Days 8 and 36; Adaptive MAD Cohort: Predose and 6 hours postdose on Days 1, and 29, Predose on Days 8 and 36</time_frame>
        <population>Participants in the PK Analysis Set for MAD cohort (with available data) and Adaptive MAD cohort were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Andecaliximab 0.3 mg/kg IV (MAD)</title>
            <description>Participants received 3 single IV infusions of andecaliximab 0.3 mg/kg on Days 1, 15, and 29.</description>
          </group>
          <group group_id="O2">
            <title>Andecaliximab 1.0 mg/kg IV (MAD)</title>
            <description>Participants received 3 single IV infusions of andecaliximab 1.0 mg/kg on Days 1, 15, and 29.</description>
          </group>
          <group group_id="O3">
            <title>Andecaliximab 2.5 mg/kg IV (MAD)</title>
            <description>Participants received 3 single IV infusions of andecaliximab 2.5 mg/kg on Days 1, 15, and 29.</description>
          </group>
          <group group_id="O4">
            <title>Andecaliximab 5.0 mg/kg IV (MAD)</title>
            <description>Participants received 3 single IV infusions of andecaliximab 5.0 mg/kg on Days 1, 15, and 29.</description>
          </group>
          <group group_id="O5">
            <title>Andecaliximab 150 mg SC (Adaptive MAD)</title>
            <description>Participants received 5 single SC doses of andecaliximab 150 mg on Days 1, 8, 15, 22, and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: Cmax (MAD)</title>
          <description>Cmax is defined as the maximum concentration of drug over the dosing interval. Data for Day 1 was based on the data collected from Day 1 through Day 8. Data for Day 29 was based on the data collected from Day 29 through Day 36.</description>
          <population>Participants in the PK Analysis Set for MAD cohort (with available data) and Adaptive MAD cohort were analyzed.</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" spread="3.23"/>
                    <measurement group_id="O2" value="33.7" spread="26.43"/>
                    <measurement group_id="O3" value="57.1" spread="13.66"/>
                    <measurement group_id="O4" value="95.3" spread="28.93"/>
                    <measurement group_id="O5" value="NA" spread="NA">Not evaluated at Day 1 for the andecaliximab 150 mg SC group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="5.06"/>
                    <measurement group_id="O2" value="29.0" spread="10.89"/>
                    <measurement group_id="O3" value="66.6" spread="15.02"/>
                    <measurement group_id="O4" value="120.8" spread="21.15"/>
                    <measurement group_id="O5" value="33.5" spread="42.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameter: Ctau (MAD)</title>
        <description>Ctau is defined as the observed drug concentration at the end of the dosing interval.</description>
        <time_frame>MAD Cohorts: Predose and 1, 2, and 6 hours postdose on Day 29; Predose on Day 36; Adaptive MAD Cohort: Predose and 6 hours postdose on Day 29; Predose on Day 36</time_frame>
        <population>Participants in the PK Analysis Set for MAD and Adaptive MAD cohorts were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Andecaliximab 0.3 mg/kg IV (MAD)</title>
            <description>Participants received 3 single IV infusions of andecaliximab 0.3 mg/kg on Days 1, 15, and 29.</description>
          </group>
          <group group_id="O2">
            <title>Andecaliximab 1.0 mg/kg IV (MAD)</title>
            <description>Participants received 3 single IV infusions of andecaliximab 1.0 mg/kg on Days 1, 15, and 29.</description>
          </group>
          <group group_id="O3">
            <title>Andecaliximab 2.5 mg/kg IV (MAD)</title>
            <description>Participants received 3 single IV infusions of andecaliximab 2.5 mg/kg on Days 1, 15, and 29.</description>
          </group>
          <group group_id="O4">
            <title>Andecaliximab 5.0 mg/kg IV (MAD)</title>
            <description>Participants received 3 single IV infusions of andecaliximab 5.0 mg/kg on Days 1, 15, and 29.</description>
          </group>
          <group group_id="O5">
            <title>Andecaliximab 150 mg SC (Adaptive MAD)</title>
            <description>Participants received 5 single SC doses of andecaliximab 150 mg on Days 1, 8, 15, 22, and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: Ctau (MAD)</title>
          <description>Ctau is defined as the observed drug concentration at the end of the dosing interval.</description>
          <population>Participants in the PK Analysis Set for MAD and Adaptive MAD cohorts were analyzed.</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Values were all below the limit of quantitation.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Values were all below the limit of quantitation.</measurement>
                    <measurement group_id="O3" value="0.8" spread="2.36"/>
                    <measurement group_id="O4" value="27.2" spread="13.99"/>
                    <measurement group_id="O5" value="16.0" spread="15.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameter: AUCinf (SAD)</title>
        <description>AUCinf is defined as the area under the plasma concentration versus time curve extrapolated to infinite time.</description>
        <time_frame>Predose and 1, 2, and 6 hours postdose on Day 1; Days 2, 3, 8, 15, 29, and 43</time_frame>
        <population>Participants in the PK Analysis Set for SAD cohorts were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Andecaliximab 0.3 mg/kg IV (SAD)</title>
            <description>Participants received a single IV infusion of andecaliximab 0.3 mg/kg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Andecaliximab 1.0 mg/kg IV (SAD)</title>
            <description>Participants received a single IV infusion of andecaliximab 1.0 mg/kg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Andecaliximab 2.5 mg/kg IV (SAD)</title>
            <description>Participants received a single IV infusion of andecaliximab 2.5 mg/kg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Andecaliximab 5.0 mg/kg IV (SAD)</title>
            <description>Participants received a single IV infusion of andecaliximab 5.0 mg/kg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: AUCinf (SAD)</title>
          <description>AUCinf is defined as the area under the plasma concentration versus time curve extrapolated to infinite time.</description>
          <population>Participants in the PK Analysis Set for SAD cohorts were analyzed.</population>
          <units>day*micrograms per milliliter(day*μg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="4.44"/>
                    <measurement group_id="O2" value="66.6" spread="22.85"/>
                    <measurement group_id="O3" value="240.8" spread="23.69"/>
                    <measurement group_id="O4" value="817.3" spread="405.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameter: AUCtau (MAD)</title>
        <description>AUCtau is defined as the area under the plasma concentration versus time curve over the dosing interval. Data for Day 1 was based on the data collected from Day 1 through Day 8. Data for Day 29 was based on the data collected from Day 29 through Day 36.</description>
        <time_frame>MAD Cohorts: Predose and 1, 2, and 6 hours postdose on Days 1 and 29; Predose on Days 8 and 36; Adaptive MAD Cohort: Predose and 6 hours postdose on Days 1, and 29; Predose on Days 8 and 36</time_frame>
        <population>Participants in the PK Analysis Set for MAD and Adaptive MAD cohorts with available data were analyzed. Concentrations fell below the limit of quantitation early in the dosing interval for some participants in some of the cohorts. Therefore, AUCtau couldn't be adequately estimated and was not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Andecaliximab 0.3 mg/kg IV (MAD)</title>
            <description>Participants received 3 single IV infusions of andecaliximab 0.3 mg/kg on Days 1, 15, and 29.</description>
          </group>
          <group group_id="O2">
            <title>Andecaliximab 1.0 mg/kg IV (MAD)</title>
            <description>Participants received 3 single IV infusions of andecaliximab 1.0 mg/kg on Days 1, 15, and 29.</description>
          </group>
          <group group_id="O3">
            <title>Andecaliximab 2.5 mg/kg IV (MAD)</title>
            <description>Participants received 3 single IV infusions of andecaliximab 2.5 mg/kg on Days 1, 15, and 29.</description>
          </group>
          <group group_id="O4">
            <title>Andecaliximab 5.0 mg/kg IV (MAD)</title>
            <description>Participants received 3 single IV infusions of andecaliximab 5.0 mg/kg on Days 1, 15, and 29.</description>
          </group>
          <group group_id="O5">
            <title>Andecaliximab 150 mg SC (Adaptive MAD)</title>
            <description>Participants received 5 single SC doses of andecaliximab 150 mg on Days 1, 8, 15, 22, and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: AUCtau (MAD)</title>
          <description>AUCtau is defined as the area under the plasma concentration versus time curve over the dosing interval. Data for Day 1 was based on the data collected from Day 1 through Day 8. Data for Day 29 was based on the data collected from Day 29 through Day 36.</description>
          <population>Participants in the PK Analysis Set for MAD and Adaptive MAD cohorts with available data were analyzed. Concentrations fell below the limit of quantitation early in the dosing interval for some participants in some of the cohorts. Therefore, AUCtau couldn't be adequately estimated and was not included.</population>
          <units>day*μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Concentrations in this group fell below the limit of quantitation early in the dosing interval. Therefore, AUCtau couldn't be adequately estimated for all participants.</measurement>
                    <measurement group_id="O2" value="79.2" spread="53.98"/>
                    <measurement group_id="O3" value="251.8" spread="88.15"/>
                    <measurement group_id="O4" value="784.8" spread="262.5"/>
                    <measurement group_id="O5" value="166.8" spread="164.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameter: AUClast (SAD)</title>
        <description>AUClast is defined as the area under the plasma concentration versus time curve from time zero to the last observable concentration.</description>
        <time_frame>Predose and 1, 2, and 6 hours postdose on Day 1; Days 2, 3, 8, 15, 29, and 43</time_frame>
        <population>Participants in the PK Analysis Set for SAD cohorts were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Andecaliximab 0.3 mg/kg IV (SAD)</title>
            <description>Participants received a single IV infusion of andecaliximab 0.3 mg/kg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Andecaliximab 1.0 mg/kg IV (SAD)</title>
            <description>Participants received a single IV infusion of andecaliximab 1.0 mg/kg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Andecaliximab 2.5 mg/kg IV (SAD)</title>
            <description>Participants received a single IV infusion of andecaliximab 2.5 mg/kg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Andecaliximab 5.0 mg/kg IV (SAD)</title>
            <description>Participants received a single IV infusion of andecaliximab 5.0 mg/kg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: AUClast (SAD)</title>
          <description>AUClast is defined as the area under the plasma concentration versus time curve from time zero to the last observable concentration.</description>
          <population>Participants in the PK Analysis Set for SAD cohorts were analyzed.</population>
          <units>day*μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="2.54"/>
                    <measurement group_id="O2" value="57.2" spread="26.96"/>
                    <measurement group_id="O3" value="212.4" spread="38.79"/>
                    <measurement group_id="O4" value="750.2" spread="412.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAD Cohorts: First dose date (Day 1) plus 30 days, MAD/Adaptive MAD Cohort: First dose date up to last dose date (Maximum: Day 29) plus 30 days.</time_frame>
      <desc>The Safety Analysis Set included participants who received at least 1 dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Andecaliximab 0.3 mg/kg IV (SAD)</title>
          <description>Participants received a single IV infusion of andecaliximab 0.3 mg/kg on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Andecaliximab 1.0 mg/kg IV (SAD)</title>
          <description>Participants received a single IV infusion of andecaliximab 1.0 mg/kg on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>Andecaliximab 2.5 mg/kg IV (SAD)</title>
          <description>Participants received a single IV infusion of andecaliximab 2.5 mg/kg on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>Andecaliximab 5.0 mg/kg IV (SAD)</title>
          <description>Participants received a single IV infusion of andecaliximab 5.0 mg/kg on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>Andecaliximab IV Combined (SAD)</title>
          <description>Participants who received a single IV infusion of andecaliximab (0.3, 1.0, 2.5 and 5.0 mg/kg on Day 1) were combined in this arm.</description>
        </group>
        <group group_id="E6">
          <title>Placebo Pooled (SAD)</title>
          <description>Participants received a single IV infusion of placebo on Day 1.</description>
        </group>
        <group group_id="E7">
          <title>Andecaliximab 0.3 mg/kg IV (MAD)</title>
          <description>Participants received 3 single IV infusions of andecaliximab 0.3 mg/kg on Days 1, 15, and 29.</description>
        </group>
        <group group_id="E8">
          <title>Andecaliximab 1.0 mg/kg IV (MAD)</title>
          <description>Participants received 3 single IV infusions of andecaliximab 1.0 mg/kg on Days 1, 15, and 29.</description>
        </group>
        <group group_id="E9">
          <title>Andecaliximab 2.5 mg/kg IV (MAD)</title>
          <description>Participants received 3 single IV infusions of andecaliximab 2.5 mg/kg on Days 1, 15, and 29.</description>
        </group>
        <group group_id="E10">
          <title>Andecaliximab 5.0 mg/kg IV (MAD)</title>
          <description>Participants received 3 single IV infusions of andecaliximab 5.0 mg/kg on Days 1, 15, and 29.</description>
        </group>
        <group group_id="E11">
          <title>Andecaliximab IV Combined (MAD)</title>
          <description>Participants who received 3 single IV infusions of andecaliximab (0.3, 1.0, 2.5, 5.0 mg/kg on Days 1, 15, and 29) were combined in this arm.</description>
        </group>
        <group group_id="E12">
          <title>Andecaliximab 150 mg SC (Adaptive MAD)</title>
          <description>Participants received 5 single SC doses of andecaliximab 150 mg on Days 1, 8, 15, 22, and 29.</description>
        </group>
        <group group_id="E13">
          <title>Andecaliximab IV+SC Combined (MAD)</title>
          <description>Participants who received 3 single IV infusions of andecaliximab (0.3, 1.0, 2.5, 5.0 mg/kg on Days 1, 15, and 29) and 5 single SC dose of andecaliximab (150 mg on Days 1, 8, 15, 22, and 29) were combined in this arm.</description>
        </group>
        <group group_id="E14">
          <title>Placebo Pooled (MAD)</title>
          <description>Participants received 3 single IV infusions of placebo on Days 1, 15, and 29.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="18" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="23" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Wandering pacemaker</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Parotid gland enlargement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Salivary gland pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:&#xD;
The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or&#xD;
The study has been completed at all study sites for at least 2 years.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gilead Clinical Study Information Center</name_or_title>
      <organization>Gilead Sciences</organization>
      <phone>1-833-445-3230 (GILEAD-0)</phone>
      <email>GileadClinicalTrials@gilead.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

